Abstract
We investigated the enzymatic efficiency and inhibition by quinolones of Mycobacterium tuberculosis DNA gyrases carrying the previously described GyrA G88C mutation and the novel GyrA G88A mutation harbored by two multidrug-resistant clinical strains and reproduced by site-directed mutagenesis. Fluoroquinolone MICs and 50% inhibitory concentrations for both mutants were 2- to 43-fold higher than for the wild type, demonstrating that these mutations confer fluoroquinolone resistance in M. tuberculosis.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antitubercular Agents / metabolism
-
Antitubercular Agents / pharmacology*
-
Binding Sites
-
DNA Gyrase / chemistry
-
DNA Gyrase / genetics*
-
DNA Gyrase / metabolism
-
Drug Resistance, Bacterial / genetics*
-
Fluoroquinolones / metabolism
-
Fluoroquinolones / pharmacology*
-
Humans
-
Microbial Sensitivity Tests
-
Models, Molecular
-
Mutagenesis, Site-Directed
-
Mutation / genetics
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / enzymology
-
Mycobacterium tuberculosis / isolation & purification
-
Protein Structure, Tertiary
Substances
-
Antitubercular Agents
-
Fluoroquinolones
-
DNA Gyrase